Concord Biotech Ltd. (CONCORDBIO) AI Stock Analysis

• Market Cap: ₹172.32B
• Dividend Yield: 0.53%
• Average Volume (3M): 6.99K
• Price to Earnings (P/E): 48.4
• Beta (1Y): 0.84
• Revenue Growth: 14.49%
• EPS Growth: 13.70%
• Country: IN
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 4.20
• Shares Outstanding: 104,616,200
• 10 Day Avg. Volume: 5,662
• 30 Day Avg. Volume: 6,989
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,860.67
• Price Target Upside: 12.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 74 Outperform
• Price Target: ₹2,057.00 ▲(24.88% Upside)

Concord Biotech Ltd.'s strong financial health and balanced technical indicators are offset by a high P/E ratio, suggesting potential overvaluation. The lack of earnings call data and new corporate events means these factors had no impact on the score.

Concord Biotech Ltd. Business Overview & Revenue Model

Company Description

Concord Biotech Ltd. (CONCORDBIO) is a prominent biopharmaceutical company engaged in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. Primarily focused on the therapeutic areas of immunosuppressants, oncology, and anti-infectives, Concord Biotech serves a global clientele with a robust portfolio of high-quality, cost-effective products. The company leverages its state-of-the-art manufacturing facilities and extensive R&D capabilities to address complex healthcare needs worldwide.

How the Company Makes Money

Concord Biotech Ltd. generates revenue through the development, production, and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations. The company's revenue streams are predominantly derived from its extensive product portfolio catering to therapeutic areas such as immunosuppressants, oncology, and anti-infectives. By supplying these critical components to pharmaceutical companies and healthcare providers globally, Concord Biotech secures a steady income. Strategic partnerships and collaborations with other pharmaceutical entities enhance its market reach and product distribution, thereby contributing significantly to its financial performance. Additionally, the company invests in continuous research and development to innovate and expand its product offerings, ensuring sustained revenue growth.

Concord Biotech Ltd. Financial Statement Overview

Summary

Concord Biotech Ltd. exhibits a strong financial position, characterized by robust revenue and profit growth with solid operational efficiency. The balance sheet is particularly strong, showcasing low leverage and high equity, which provides financial stability. Cash flow management is effective, though variability in free cash flow growth suggests a need for cautious future capital planning.

Income Statement

Concord Biotech Ltd. has demonstrated strong revenue growth over the years, with a notable increase from 2020 to 2025. Gross profit margin and net profit margin are robust, reflecting efficient cost management and operational success. The EBIT and EBITDA margins indicate solid profitability, with consistent growth. However, the gross profit margin has slightly decreased, signaling potential cost pressures that need monitoring.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio, indicating minimal financial leverage and risk. The equity ratio is high, showing significant equity financing. Return on equity is commendable, highlighting effective use of shareholder funds. Overall, the company shows financial stability and prudent financial management.

Cash Flow

Operating cash flow is consistently positive and growing, underscoring effective cash management. Free cash flow also shows positive trends, although growth has fluctuated across the years. The operating cash flow to net income ratio is favorable, indicating good cash conversion from profits. However, the free cash flow growth rate has been inconsistent, presenting potential challenges in sustaining capital investments.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	12.00B	9.98B	8.53B	7.08B	6.04B
Gross Profit	5.89B	7.53B	6.73B	5.31B	4.84B
EBITDA	5.51B	4.66B	3.83B	2.97B	3.42B
Net Income	3.72B	3.08B	2.40B	1.75B	2.35B
Balance Sheet
Total Assets	20.34B	17.01B	15.14B	13.13B	11.83B
Cash, Cash Equivalents and Short-Term Investments	3.18B	2.86B	1.72B	1.62B	2.01B
Total Debt	29.69M	97.38M	315.47M	624.93M	892.83M
Total Liabilities	2.22B	1.74B	2.24B	2.10B	1.83B
Stockholders Equity	18.13B	15.27B	12.90B	11.03B	9.99B
Cash Flow
Free Cash Flow	1.36B	1.80B	1.01B	519.70M	-373.59M
Operating Cash Flow	2.47B	2.65B	2.46B	2.07B	1.67B
Investing Cash Flow	-1.63B	-1.55B	-1.58B	-1.12B	-1.95B
Financing Cash Flow	-986.67M	-992.15M	-852.19M	-1.00B	311.24M

Concord Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1647.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Negative. The current price of 1647.15 is below the 20-day moving average (MA) of 1797.91, below the 50-day MA of 1852.49, and below the 200-day MA of 1861.59, indicating a bearish trend. The MACD of -58.26 indicates Positive momentum. The RSI at 27.08 is Positive, neither overbought nor oversold. The STOCH value of 13.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CONCORDBIO.

Concord Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CONCORDBIO	74 Outperform	₹172.32B	48.39		0.53%	14.49%	13.70%
SYNGENE	68 Neutral	₹261.71B	51.40		0.19%	7.41%	2.88%
BLUEJET	68 Neutral	₹134.57B	37.52		0.13%	75.82%	127.85%
PPLPHARMA	60 Neutral	₹251.69B	255.98		0.07%	9.08%	249.08%
JUBLINGREA	58 Neutral	₹111.00B	39.61		0.71%	2.60%	60.61%
BIOCON	54 Neutral	₹473.59B	110.73		0.14%	6.80%	-75.66%
Sector *	51 Neutral	kr6.00B	8.78	-28.70%	2.24%	51.61%	19.20%

Concord Biotech Ltd. Corporate Events

Concord Biotech Releases Q1 2025 Financial Results

Concord Biotech Ltd. has released an investor presentation detailing its financial results for the first quarter ending June 30, 2025. This announcement is part of the company’s compliance with SEBI regulations, aiming to keep stakeholders informed about its financial performance. The presentation may impact investor perceptions and market positioning by providing insights into the company’s operational and financial health.